Management of patent foramen ovale in cryptogenic stroke.

[en] There is currently no consensus on the optimal management of cryptogenic stroke in the presence of a patent foramen ovale (PFO). Some physicians do not believe in the added value of PFO closure in cryptogenic stroke, whereas, for others, cryptogenic stroke represents a situation where PFO closure would be the best management. Because of a lack of well-designed randomized trials, guidelines do not provide a clear answer. Therefore, the cardiological and neurovascular societies in Belgium decided to write an attempt at an expert opinion paper.

Disciplines :

Cardiovascular & respiratory systems

Author, co-author :

Budts, Werner

Legrand, Victor ; Université de Liège - ULiège > Département des sciences cliniques > Cardiologie

Peeters, Andre

Thijs, Vincent

Language :

English

Title :

Management of patent foramen ovale in cryptogenic stroke.

Publication date :

2012

Journal title :

Acta Cardiologica

ISSN :

0001-5385

eISSN :

1784-973X

Publisher :

Association Royale des Sociétés Scientifiques Medicales Belges/Koninklijke Vereniging van de Belgische Medische Wetenschappelijke Genootschappen, Bruxelles, Belgium

Volume :

Issue :

Pages :

3-9

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 26 May 2014

Statistics

Number of views

104 (1 by ULiège)

Number of downloads

642 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Windecker S, Meier B. Is closure recommended for patent foramen ovale and cryptogenic stroke? Patent foramen ovale and cryptogenic stroke: to close or not to close? Closure: what else! Circulation 2008; 118: 1989-98.
Moore K. The Developing Human: Clinically Oriented Embryology. Ed. 6, Philadelphia, PA, Saunders, 1998.
Olivares-Reyes A, Chan S, Lazar EJ, Bandlamudi K, Narla V, Ong K. Atrial septal aneurysm: a new classification in two hundred five adults. J Am Soc Echocardiogr 1997; 10: 644-56.
Marazanof M, Roudaut R, Cohen A, Tribouilloy C, Malergues MC, Halphen C, Bussiere JL, Schultz R, Marcaggi X, Lardoux H, Bruntz JF, Coisnes D, Brandt CM, Marchal C, Letenneur L, Bonnet J. Atrial septal aneurysm. Morphological characteristics in a large population: pathological associations. A French multicenter study on 259 patients investigated by transoesophageal echocardiography. Int J Cardiol 1995; 52: 59-65.
Vick GW. Defects of the atrial septum including atrioventricular septal defects. In: Garson A, Jr, Bricker JT, Fisher DJ, Neish SR. The Science and Practice of Pediatric Cardiology, 2nd edition. Baltimore, MD: Williams & Wilkins, 1998: 1141-79.
Lynch JJ, Schuchard GH, Gross CM, Wann LS. Prevalence of right-to-left atrial shunting in a healthy population: detection by Valsalva maneuver contrast echocardiography. Am J Cardiol 1984; 53: 1478-80.
Sloan MA, Alexandrov AV, Tegeler CH, Spencer MP, Caplan LR, Feldmann E, Wechsler LR, Newell DW, Gomez CR, Babikian VL, Lefkowitz D, Goldman RS, Armon C, Hsu CY, Goodin DS. Assessment: transcranial Doppler ultrasonography: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2004; 62: 1468-81.
Di Tullio M, Sacco RL, Venketasubramanian N, Sherman D, Mohr JP, Homma S. Comparison of diagnostic techniques for the detection of a patent foramen ovale in stroke patients. Stroke 1993; 24: 1020-4.
Lechat P, Mas JL, Lascault G, Loron P, Theard M, Klimczac M, Drobinski G, Thomas D, Grosgogeat Y. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 1988; 318: 1148-52.
Lamy C, Giannesini C, Zuber M, Arquizan C, Meder JF, Trystram D, Coste J, Mas JL. Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen ovale: the PFO-ASA Study. Atrial Septal Aneurysm. Stroke 2002; 33: 706-11.
Elijovich L, Josephson SA, Fung GL, Smith WS. Intermittent atrial fibrillation may account for a large proportion of otherwise cryptogenic stroke: a study of 30-day cardiac event monitors. J Stroke Cerebrovasc Dis 2009; 18: 185-9.
Alsheikh-Ali AA, Thaler DE, Kent DM. Patent foramen ovale in cryptogenic stroke: incidental or pathogenic? Stroke 2009; 40: 2349-55.
Martin F, Sanchez PL, Doherty E, Colon-Hernandez PJ, Delgado G, Inglessis I, Scott N, Hung J, King ME, Buonanno F, Demirjian Z, de Moor M, Palacios IF. Percutaneous transcatheter closure of patent foramen ovale in patients with paradoxical embolism. Circulation 2002; 106: 1121-6.
Meier B. Closure of patent foramen ovale: technique, pitfalls, complications, and follow up. Heart 2005; 91: 444-8.
Windecker S, Wahl A, Chatterjee T, Garachemani A, Eberli FR, Seiler C, Meier B. Percutaneous closure of patent foramen ovale in patients with paradoxical embolism: long-term risk of recurrent thromboembolic events. Circulation 2000; 101: 893-8.
Krumsdorf U, Ostermayer S, Billinger K, Trepels T, Zadan E, Horvath K, Sievert H. Incidence and clinical course of thrombus formation on atrial septal defect and patient foramen ovale closure devices in 1,000 consecutive patients. J Am Coll Cardiol 2004; 43: 302-9.
De Castro S, Cartoni D, Fiorelli M, Rasura M, Anzini A, Zanette EM, Beccia M, Colonnese C, Fedele F, Fieschi C, Pandian NG. Morphological and functional characteristics of patent foramen ovale and their embolic implications. Stroke 2000; 31: 2407-13.
Lee JY, Song JK, Song JM, Kang DH, Yun SC, Kang DW, Kwon SU, Kim JS. Association between anatomic features of atrial septal abnormalities obtained by omni-plane transesophageal echocardiography and stroke recurrence in cryptogenic stroke patients with patent foramen ovale. Am J Cardiol 2010; 106: 129-34.
Furlan AJ, Reisman M, Massaro J, Mauri L, Adams H, Albers GW, Felberg R, Herrmann H, Kar S, Landzberg M, Raizner A, Wechsler L. Study design of the CLOSURE I Trial: a prospective, multicenter, randomized, controlled trial to evaluate the safety and efficacy of the STARFlex septal closure system versus best medical therapy in patients with stroke or transient ischemic attack due to presumed paradoxical embolism through a patent foramen ovale. Stroke 2010; 41: 2872-83.
Khattab AA, Windecker S, Juni P, Hildick-Smith D, Dudek D, Andersen HR, Ibrahim R, Schuler G, Walton AS, Wahl A, Mattle HP, Meier B. Randomized clinical trial comparing percutaneous closure of patent foramen ovale (PFO) using the Amplatzer PFO Occluder with medical treatment in patients with cryptogenic embolism (PC-Trial): rationale and design. Trials 2011; 12: 56.
O'Gara PT, Messe SR, Tuzcu EM, Catha G, Ring JC. Percutaneous device closure of patent foramen ovale for secondary stroke prevention: a call for completion of randomized clinical trials. A science advisory from the American Heart Association/ American Stroke Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2009; 53: 2014-8.
O'Gara PT, Messe SR, Tuzcu EM, Catha G, Ring JC. Percutaneous device closure of patent foramen ovale for secondary stroke prevention: a call for completion of randomized clinical trials: a science advisory from the American Heart Association/ American Stroke Association and the American College of Cardiology Foundation. Circulation 2009; 119: 2743-7.
Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick P, Halperin J, Harbaugh R, Johnston SC, Katzan I, Kelly-Hayes M, Kenton EJ, Marks M, Schwamm LH, Tomsick T. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation 2006; 113: e409-449.
Torti SR, Billinger M, Schwerzmann M, Vogel R, Zbinden R, Windecker S, Seiler C. Risk of decompression illness among 230 divers in relation to the presence and size of patent foramen ovale. Eur Heart J 2004; 25: 1014-20.
Cheng TO. Transcatheter closure of patent foramen ovale: a definitive treatment for platypnea-orthodeoxia. Catheter Cardiovasc Interv 2000; 51: 120.
Budts W. Relationship between migraine and right-to-left shunt in children: editorial. Eur J Pediatr 2011; 170: 275-7.
Post MC, Budts W. The relationship between migraine and right-to-left shunt: Fact or fiction? Chest 2006; 130: 896-901.
Dowson A, Mullen MJ, Peatfield R, Muir K, Khan AA, Wells C, Lipscombe SL, Rees T, De Giovanni JV, Morrison WL, Hildick-Smith D, Elrington G, Hillis WS, Malik IS, Rickards A: Migraine Intervention With STARFlex Technology (MIST) trial: a prospective, multicenter, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache. Circulation 2008; 117: 1397-1404.
Tepper SJ, Cleves C, Taylor FR. Patent foramen ovale and migraine: association, causation, and implications of clinical trials. Curr Pain Headache Rep 2009; 13: 221-6.
Bonvini RF, Sztajzel R, Dorsaz PA, Righini M, Bonvin C, Alibegovic J, Sigwart U, Camenzind E, Verin V, Sztajzel J. Incidence of atrial fibrillation after percutaneous closure of patent foramen ovale and small atrial septal defects in patients presenting with cryptogenic stroke. Int J Stroke 2010; 5: 4-9.
Wahl A, Krumsdorf U, Meier B, Sievert H, Ostermayer S, Billinger K, Schwerzmann M, Becker U, Seiler C, Arnold M, Mattle HP, Windecker S. Transcatheter treatment of atrial septal aneurysm associated with patent foramen ovale for prevention of recurrent paradoxical embolism in high-risk patients. J Am Coll Cardiol 2005; 45: 377-80.
Shafi NA, McKay RG, Kiernan FJ, Silverman IE, Ahlquist M, Silverman DI. Determinants and clinical significance of persistent residual shunting in patients with percutaneous patent foramen ovale closure devices. Int J Cardiol 2009; 137: 314-6.